Get started
Author

Ritesh Patil

Clinical trial results of the HER‐2/ neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients
2011 · Elizabeth A. Mittendorf, Guy T. Clifton, et al. · Cancer · 174
Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial
2009 · Ritesh Patil, Guy T. Clifton, et al. · Journal of the American College of Surgeons · 51
Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence
2008 · Jarrod P. Holmes, Jeremy D. Gates, et al. · Cancer · 50
PDF
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine
2010 · Jarrod P. Holmes, Guy T. Clifton, et al. · Cancer · 49
PDF
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
2014 · Elizabeth Ann Mittendorf, Erika J Schneble, et al. · Journal of Clinical Oncology · 10
Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine
2012 · TJ Vreeland, GT Clifton, et al. · Cancer Research · 7
Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.
2013 · Ritesh Patil, Guy T. Clifton, et al. · Journal of Clinical Oncology · 4
From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines.
2012 · Timothy J Vreeland, Diane F Hale, et al. · Journal of Clinical Oncology · 3
An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.
2012 · Diane F Hale, Sonia A. Perez, et al. · Journal of Clinical Oncology · 3
Biomarker correlation to clinical response in phase I/II trials of the adjuvant breast cancer vaccine neuvax (nelipepimut-S or E75).
2013 · John S. Berry, Alfred F Trappey, et al. · Journal of Clinical Oncology · 2
Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine.
2012 · Raetasha Sheavette Dabney, Diane F Hale, et al. · Journal of Clinical Oncology
Abstract P2-20-01: Safety and Clinical Efficacy of Multiple Booster Inoculations with the E75 Adjuvant Breast Cancer Vaccine
2010 · TJ Vreeland, GT Clifton, et al. · Cancer Research
MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines
2010 · Juan Gu, Patil Ritesh, et al. · Blood
Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations.
2010 · G. T. Clifton, K. S. Clive, et al. · Journal of Clinical Oncology
Abstract LB-322: A modified HER2/neu peptide vaccine (2L9V-GP2) demonstrates enhanced CD8+ T cell recognition and stimulation in breast cancer patients at high risk for recurrence
2010 · Ritesh Patil, Guy T. Clifton, et al. · Cancer Research
Abstract LB-329: Defining rgulatory T-cells as CD4+CD25hiCD127- or as CD4+CD25hiFoxP3+ in immune monitoring of cancer vaccine clinical trials
2010 · Guy T. Clifton, Ritesh Patil, et al. · Cancer Research
Works count: 16
Citation count: 353
H-index: 6
I10-index: 5
Year
Topic
Type